| Jul 31 |
Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7
|
| Jul 2 |
Unveiling 6 Analyst Insights On Capricor Therapeutics
|
| Jul 1 |
Capricor Therapeutics to join Russell 2000 Index
|
| Jul 1 |
Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
|
| Jul 1 |
Capricor’s cell therapy shows three year benefit in DMD patients
|
| Jun 28 |
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
|
| Jun 25 |
CORRECTION: Capricor Therapeutics
|
| Jun 25 |
Capricor gains FDA pre-BLA meeting on deramiocel for Duchenne muscular dystrophy
|
| Jun 25 |
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
|
| Jun 17 |
Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going
|
